Leuprorelin(CAS: 53714-56-0)

Clinical use

Leuprolide has been tested as a treatment for reducing sexual urges in pedophiles and other cases

of paraphilia. High doses are sometimes used to chemically castrate sex offenders.

Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer’s disease.

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under

the brand name Eligard, and by TAP Pharmaceuticals (1985–2008), by Varian Darou Pajooh under the

brand name Leupromer and Abbott Laboratories (2008-current) under the brand name Lupron. It is

available as a slow-release implant or subcutaneous/intramuscular injection.

In the UK and Ireland, leuprorelin is marketed by Takeda UK as Prostap SR 

(one-month injection) and Prostap 3 (three-month injection).